ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). The lawsuit alleges Defendants made materially false and misleading statements and/or failed to disclose material adverse information regarding its business, operations, and compliance policies, including allegations that: (i) the Company failed to maintain adequate and effective data management controls and procedures related to its drug research programs; (ii) as a result, the data published in support of simufilam were susceptible to manipulation to overstate the drug's effectiveness; (iii) accordingly, Cassava had misrepresented the ...
SAVA) Class Action – Nationally Ranked Investors' Rights Firm Encourages Investors With Significant Losses to Contact the Firm>Full story available on Benzinga.com